Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - capmatinibum - filmtabletten - capmatinibum 150 mg ut capmatinibi hydrochloridum monohydricum, cellulosum microcristallinum, mannitolum, crospovidonum, povidonum k 30, magnesii stearas, silica colloidalis anhydrica, natrii laurilsulfas corresp. natrium 0.12 mg, Überzug: hypromellosum, e 171, macrogolum 4000, talcum, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - nicht-kleinzelliges lungenkarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - capmatinibum - filmtabletten - capmatinibum 200 mg ut capmatinibi hydrochloridum monohydricum, cellulosum microcristallinum, mannitolum, crospovidonum, povidonum k 30, magnesii stearas, silica colloidalis anhydrica, natrii laurilsulfas corresp. natrium 0.16 mg, Überzug: hypromellosum, e 171, macrogolum 4000, talcum, e 172 (flavum), pro compresso obducto. - nicht-kleinzelliges lungenkarzinom - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karzinom, nicht kleinzellige lunge - antineoplastische mittel - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.